Skip to main content

iBio, Inc.

corporate_fare Company Profile

iBio, Inc.

IBIO·NASDAQ·Life Sciences·CIK 0001420720

iBio, Inc. is a preclinical stage biotechnology company that uses Artificial Intelligence (AI) to develop precision antibodies for cardiometabolic and obesity conditions. The company's core mission is to use AI and machine learning (ML) to discover new biologics that have been difficult for other scientists to develop. Through its AI Drug Discovery Platform, iBio has identified distinct molecules designed to address needs not met by current glucagon-like peptide-1 (GLP-1) receptor agonists. The company is developing second-generation therapies to address challenges with current GLP-1 receptor agonists, such as muscle loss, fat regain after treatment cessation, and long-term tolerability, by using AI-guided antibody design and advanced screening technologies. iBio's obesity strategy focuses on three principles: developing next-generation antibody therapeutics to preserve muscle mass, selectively target fat, and provide durable weight loss with improved tolerability; focusing on targets with strong human validation to reduce development risk and increase clinical success likelihood; and applying its integrated AI Drug Discovery Platform and scientific expertise to rapidly generate development-ready biologics. The company is also developing its existing immune-oncology preclinical pipeline and seeking strategic partners to advance these programs. All discovery and development work is conducted at iBio's San Diego research and development (R&D) laboratory space.

iBio, Inc. (NASDAQ:IBIO) is a publicly traded company in the Life Sciences sector. Wiseek monitors IBIO SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • iBio Doses First Patient in Phase 1 Trial for Obesity Drug IBIO-600, Now a Clinical-Stage Company
  • iBio Extends Cash Runway to Q4 Fiscal 2028, Bolstering Financial Outlook
  • iBio Reports Stronger Liquidity, Extends Cash Runway to Q4 2028, Advances Clinical Pipeline
  • iBio Resolves Going Concern, Extends Cash Runway to Q4 2028, and Expands Pipeline
  • iBio Appoints Biotech Veteran Dr. Elizabeth Stoner to Board, Strengthening Clinical Development Expertise

Financial Snapshot

Fiscal year ended June 30, 2025
Revenue
$400K
Net Income
-$18.38M
Diluted EPS
-$1.75
Op. Cash Flow
-$15.3M
Free Cash Flow
-$15.32M
Operating Income
-$18.6M
Cash & Equivalents
$8.58M
Debt / Equity
0.00×
Net Margin
-45.94×
Shares Outstanding
19.35M sh
Source: 10-K · filed 2025-09-05 · accession 0001558370-25-011888

Recent Capital Actions

  • 2026-03-06 Proposed Cash ↑ +$24.3M

    sequent to December 31, 2025, to: (i) the issuance of 1,079,391 shares of Common Stock upon the exercise of pre-funded warrants and our receipt of the aggregate exercise price of $1,079; (ii) the issuance of 1,408,481…

  • 2026-03-06 Proposed Shares outstanding (snapshot) 34.54M sh

    us for a discussion of factors to consider before deciding to purchase shares of our Common Stock. Nasdaq Capital Market Trading Symbol IBIO Unless we indicate otherwise, all information in this prospectus supplement is…

  • 2026-02-27 Proposed Mixed Capital Action +$24.3M

    this offering. After giving effect, subsequent to December 31, 2025, to: (i) the issuance of 1,079,391 shares of Common Stock upon the exercise of pre-funded warrants and our receipt of the aggregate exercise price of…

  • 2026-02-27 Proposed Mixed Capital Action 2.37 sh

    alue per share as of December 31, 2025 $ 2.34 Increase in pro forma net tangible book value per share attributable to this offering $ 0.03 Pro forma as adjusted net tangible book value per share as of December 31, 2025…

Detected from SEC filings (8-K, S-4, POS AM, 6-K). Last 12 months.
Browse all tickers starting with I →
$1.73 +0.04% today
52-week range · as of 2026-05-12 $0.5562 – $3.82
Market cap
$83.96M
Volume
455.7K (0.5× avg)
3-mo avg 853.8K
Live data · 2026-06-14 06:17 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed IBIO - Latest Insights

IBIO
Jun 02, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
iBio Doses First Patient in Phase 1 Trial for Obesity Drug IBIO-600, Now a Clinical-Stage Company
Price at Filing: $1.89
Real-time Price: $1.73 info
Change: -$0.155 (-8%) info
Market Cap: $83.957M info
Sentiment: Positive
View Wiseek Article
IBIO
May 12, 2026, 4:19 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
iBio Extends Cash Runway to Q4 Fiscal 2028, Bolstering Financial Outlook
Price at Filing: $1.58
Real-time Price: $1.73 info
Change: +$0.150 (+9%) info
Market Cap: $83.957M info
Sentiment: Positive
View Wiseek Article
IBIO
May 12, 2026, 4:18 PM EDT
Filing Type: 10-Q
Importance Score:
8
iBio Reports Stronger Liquidity, Extends Cash Runway to Q4 2028, Advances Clinical Pipeline
Price at Filing: $1.66
Real-time Price: $1.73 info
Change: +$0.070 (+4%) info
Market Cap: $83.957M info
Sentiment: Positive
View Wiseek Article
IBIO
May 12, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
8
iBio Resolves Going Concern, Extends Cash Runway to Q4 2028, and Expands Pipeline
Price at Filing: $1.66
Real-time Price: $1.73 info
Change: +$0.070 (+4%) info
Market Cap: $83.957M info
Sentiment: Positive
View Wiseek Article
IBIO
May 08, 2026, 4:16 PM EDT
Filing Type: 8-K
Importance Score:
7
iBio Appoints Biotech Veteran Dr. Elizabeth Stoner to Board, Strengthening Clinical Development Expertise
Price at Filing: $1.73
Real-time Price: $1.73 info
Change: +$0.0026 (+0.15%) info
Market Cap: $83.957M info
Sentiment: Positive
View Wiseek Article
IBIO
Apr 17, 2026, 5:13 PM EDT
Filing Type: 8-K/A
Importance Score:
8
iBio Details Accelerated Warrant Expiration, Potential 30% Dilution Following Clinical Trial Announcement
Price at Filing: $2.03
Real-time Price: $1.73 info
Change: -$0.300 (-15%) info
Market Cap: $83.957M info
Sentiment: Negative
View Wiseek Article
IBIO
Apr 08, 2026, 9:00 AM EDT
Filing Type: 8-K
Importance Score:
8
iBio Initiates Phase 1 Trial for IBIO-600; Triggers Expiration of Highly Dilutive Warrants
Price at Filing: $2.30
Real-time Price: $1.73 info
Change: -$0.5695 (-25%) info
Market Cap: $83.957M info
Sentiment: Neutral
View Wiseek Article
IBIO
Apr 08, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
iBio Gains Regulatory Clearance for IBIO-600 Phase 1 Trial in Australia, Entering Clinical Stage
Price at Filing: $2.24
Real-time Price: $1.73 info
Change: -$0.510 (-23%) info
Market Cap: $83.957M info
Sentiment: Positive
View Wiseek Article
IBIO
Mar 09, 2026, 7:04 AM EDT
Filing Type: 8-K
Importance Score:
7
iBio Reports Positive Preclinical Data for Fat-Selective Weight Loss Drug IBIO-610 and Expands Pipeline
Price at Filing: $2.46
Real-time Price: $1.73 info
Change: -$0.730 (-30%) info
Market Cap: $83.957M info
Sentiment: Positive
View Wiseek Article
IBIO
Mar 06, 2026, 5:25 PM EST
Filing Type: 424B5
Importance Score:
9
iBio Activates $100M At-The-Market Offering, Posing Significant Dilution Risk
Price at Filing: $2.56
Real-time Price: $1.73 info
Change: -$0.830 (-32%) info
Market Cap: $83.957M info
Sentiment: Negative
View Wiseek Article
IBIO
Feb 27, 2026, 4:49 PM EST
Filing Type: 8-K
Importance Score:
8
iBio Establishes New $100M At-The-Market Offering Program, Terminating Prior Smaller Facility
Price at Filing: $2.80
Real-time Price: $1.73 info
Change: -$1.07 (-38%) info
Market Cap: $83.957M info
Sentiment: Negative
View Wiseek Article
IBIO
Feb 27, 2026, 4:40 PM EST
Source: Reuters
Importance Score:
9
iBio Files for $200M Mixed Shelf Offering, Signaling Substantial Future Dilution
Price at Filing: $2.81
Real-time Price: $1.73 info
Change: -$1.08 (-38%) info
Market Cap: $83.957M info
Sentiment: Negative
View Wiseek Article
IBIO
Feb 27, 2026, 4:23 PM EST
Filing Type: S-3
Importance Score:
8
iBio Files $200M Universal Shelf, Including $100M At-The-Market Offering for Capital Raise
Price at Filing: $2.80
Real-time Price: $1.73 info
Change: -$1.07 (-38%) info
Market Cap: $83.957M info
Sentiment: Negative
View Wiseek Article
IBIO
Feb 10, 2026, 4:16 PM EST
Filing Type: 10-Q
Importance Score:
7
iBio Reports Q2 FY26 Results, Resolves Going Concern Doubt with Extended Cash Runway
Price at Filing: $2.26
Real-time Price: $1.73 info
Change: -$0.530 (-23%) info
Market Cap: $83.957M info
Sentiment: Neutral
View Wiseek Article
IBIO
Feb 10, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
7
iBio Extends Cash Runway into FY28 with $26M Financing, Advances Key Preclinical Programs
Price at Filing: $2.26
Real-time Price: $1.73 info
Change: -$0.530 (-23%) info
Market Cap: $83.957M info
Sentiment: Positive
View Wiseek Article
IBIO
Feb 09, 2026, 5:29 PM EST
Filing Type: 424B3
Importance Score:
8
Final Prospectus Filed for Resale of 11 Million Shares, Confirming 34% Dilution
Price at Filing: $2.47
Real-time Price: $1.73 info
Change: -$0.740 (-30%) info
Market Cap: $83.957M info
Sentiment: Negative
View Wiseek Article
IBIO
Jan 30, 2026, 4:10 PM EST
Filing Type: S-3
Importance Score:
8
iBio Registers Over 11 Million Shares for Resale by Investors from Recent $26M Private Placement
Price at Filing: $2.09
Real-time Price: $1.73 info
Change: -$0.360 (-17%) info
Market Cap: $83.957M info
Sentiment: Negative
View Wiseek Article
IBIO
Jan 12, 2026, 5:29 PM EST
Filing Type: 8-K
Importance Score:
8
iBio Secures $26M in Dilutive Private Placement to Fund Preclinical Programs and Extend Cash Runway
Price at Filing: $2.76
Real-time Price: $1.73 info
Change: -$1.03 (-37%) info
Market Cap: $83.957M info
Sentiment: Negative
View Wiseek Article